---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-132586"
form_type: "8-K"
ticker: null
cik: "0001567514"
company_name: "Intra-Cellular Therapies, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T18:20:38.113134+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Intra-Cellular Therapies Q1: $144.8M CAPLYTA sales (+53% YoY), loss narrows; Ph3 MDD success

## Summary
- Net product sales of CAPLYTA $144.8M, up 53% from $94.7M YoY; net loss $15.2M vs $44.1M.
- Positive Phase 3 Study 501 results: lumateperone adjunctive MDD met primary (MADRS, p<0.0001) and key secondary endpoints.
- FY 2024 guidance reiterated: CAPLYTA sales $645-$675M, SG&A $450-$480M, R&D $215-$240M.
- Completed $543M net public offering of ~7.9M shares in April 2024; cash $477.4M at Q1 end.
- Expect to report Study 502 topline results late Q2 2024; sNDA filing planned H2 2024.

## SEC filing metadata
- accession: 0001193125-24-132586
- form_type: 8-K
- cik: 0001567514
- company_name: Intra-Cellular Therapies, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567514/000119312524132586/0001193125-24-132586-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567514/000119312524132586/d826948d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-132586
- JSON: https://secwatch.observer/filing/0001193125-24-132586.json
- Plain text: https://secwatch.observer/filing/0001193125-24-132586.txt

## Key facts
- Earnings Releases
  Intra-Cellular Therapies, Inc. reported the first quarter ended March 31, 2024 results: revenue $144.9 million, net income Net loss for the first quarter of 2024 was $15.2 million. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $144.9 million
  - Net income: Net loss for the first quarter of 2024 was $15.2 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Total revenues were $144.9 million for the first quarter of 2024, compared to $95.3 million for the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567514/000119312524132586/0001193125-24-132586-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.